In the ever-evolving landscape of medical diagnostics, the question is not just about “How do you test for pancreatic cancer?” but “What’s the most effective way to test for it?”
Among the tools available for pancreatic cancer testing, the biomarker CA19-9 has gained attention for its potential role in monitoring and diagnosis of the disease. In this blog post, we’ll explore what CA19-9 is, how it is used in pancreatic cancer testing, and its limitations as a biomarker.
Pancreatic cancer is a serious disease with more than 60,000 new cases each year in the U.S. and with expanded impact, that affects a substantial number of people. It’s the third leading cause of cancer-related deaths, and it’s predicted to become the second leading cause by 2030.